Nitsan Halevy
Chief Tech/Sci/R&D Officer at PLURI INC.
Nitsan Halevy active positions
| Companies | Position | Start | End |
|---|---|---|---|
| PLURI INC. | Chief Tech/Sci/R&D Officer | 2021-02-28 | - |
Career history of Nitsan Halevy
Former positions of Nitsan Halevy
| Companies | Position | Start | End |
|---|---|---|---|
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | - | - |
Training of Nitsan Halevy
| Ben-Gurion University of the Negev | Doctorate Degree |
Statistics
International
| Israel | 3 |
| United States | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| PLURI INC. | Health Technology |
| Private companies | 1 |
|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
- Stock Market
- Insiders
- Nitsan Halevy
- Experience
